AZD-3161
AZD-3161
AZD-3161 is an investigational pharmaceutical compound developed by AstraZeneca, primarily researched for its potential applications in oncology. It is classified as a small molecule inhibitor targeting specific pathways involved in cancer cell proliferation and survival.
Mechanism of Action[edit | edit source]
AZD-3161 functions by inhibiting key enzymes involved in the signaling pathways that regulate cell growth and division. Specifically, it targets the PI3K/AKT/mTOR pathway, which is often dysregulated in various types of cancer. By blocking this pathway, AZD-3161 aims to reduce tumor growth and induce apoptosis in cancer cells.
Clinical Development[edit | edit source]
AZD-3161 is currently undergoing clinical trials to evaluate its efficacy and safety in treating different forms of cancer. The trials are designed to assess its impact on tumor size, progression-free survival, and overall survival rates in patients. Early-phase trials have shown promising results, leading to further investigation in larger, more comprehensive studies.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of AZD-3161 includes its absorption, distribution, metabolism, and excretion characteristics. It is administered orally, and studies have shown that it has a favorable bioavailability. The compound is metabolized primarily in the liver, and its metabolites are excreted through the renal and biliary systems.
Side Effects[edit | edit source]
As with many targeted cancer therapies, AZD-3161 may cause a range of side effects. Common adverse effects observed in clinical trials include nausea, fatigue, diarrhea, and skin rash. More serious side effects, although less common, may include liver toxicity and hematological abnormalities. Ongoing studies aim to better understand the safety profile of AZD-3161 and manage any potential risks associated with its use.
Future Directions[edit | edit source]
Research on AZD-3161 continues to explore its potential in combination therapies, where it is used alongside other anticancer agents to enhance therapeutic outcomes. Additionally, studies are investigating its role in overcoming resistance to existing treatments, a significant challenge in oncology.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
| Products | |
|---|---|
| Predecessors and acquired companies | |
| People | |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
